Rottendorf Pharma and Corealis Pharma have announced a strategic partnership aimed at enhancing the development and manufacturing of oral solid dosage (OSD) forms. This collaboration seeks to streamline the end-to-end OSD process for pharmaceutical and biotech companies by integrating complementary development capabilities, thereby reducing risks associated with the journey from pre-formulation to global market supply.
The partnership formalizes an existing collaboration that focuses on a development-to-commercialization model characterized by early technical integration of materials, equipment, and process consistency. This allows companies to transition smoothly from pre-clinical and early clinical phases at Corealis to Phase III scale-up and market registration at Rottendorf. By aligning formulation strategies, analytical methods, and manufacturing processes, the partnership aims to mitigate scale-up risks and accelerate timelines, ultimately enhancing commercial readiness.
Rottendorf’s extensive experience in late-stage development and commercial manufacturing complements Corealis’s expertise in early-stage development. This collaboration not only facilitates a seamless knowledge transfer but also provides a structured framework for data exchange and project management. With the aim of delivering a flexible yet integrated solution, the partnership is poised to support clients in navigating the complexities of drug development and commercialization efficiently.
Start your 7-day trial and see what the database can do →
